Methods and compositions for inhibition of immune responses and autoimmunity

Inventors

Barrat, Franck • Coffman, Robert L. • Matray, Tracy • Guiducci, Cristiana

Assignees

Dynavax Technologies Corp

Interested in licensing this patent?

MTEC can help explore whether this patent might be available for licensing for your application.

Publication Number

US-9476053-B2

Patent

Publication Date

2016-10-25

Expiration Date


Abstract

The application relates to the use of immunoregulatory polynucleotides and/or immunoregulatory compounds in combination with other therapeutic agents. The application further relates to immunoregulatory polynucleotides and/or immunoregulatory compounds comprising a modified immunoregulatory sequence. It also relates to the administration of the immunoregulatory polynucleotides and/or immunoregulatory compounds comprising a modified immunoregulatory sequence to regulate an immune response.

Core Innovation

The disclosure concerns immunoregulatory polynucleotides and compounds that inhibit TLR7- and/or TLR9-mediated immune responses. The independent claim covers a polynucleotide combining a TLR7-inhibitory sequence near its 5′ end with a TLR9-inhibitory sequence containing at least one inosine. Additional sequence-level, length, and composition constraints are [procedural detail omitted for safety]. Dependent claims address modifications, specified forms, compositions, kits, and methods of inhibiting an immune response.

Evaluated cell and animal studies report inhibition of TLR7- and TLR9-associated cytokine responses, including in human plasmacytoid dendritic cells, B cells, and mice. The disclosure describes use in autoimmune and chronic inflammatory disorders, corticosteroid-related responses, and suppression of immune responses to microbial nucleic acids or gene-therapy vectors. Reported animal models also demonstrate reduced inflammatory gene expression and modulation of responses associated with viral induction.

Claims Coverage

The provided claims identify one independent claim with one inventive feature.

Polynucleotide combining TLR7- and TLR9-inhibitory sequences

The independent claim covers a polynucleotide combining a TLR7-inhibitory sequence near its 5′ end with a TLR9-inhibitory sequence containing at least one inosine, subject to specified length and sequence-composition constraints, where additional sequence-level constraints are [procedural detail omitted for safety].

The independent claim covers the combined inhibitory sequences and their specified placement, length, and composition, while dependent claims address modifications, specified forms, compositions, kits, and methods of inhibiting an immune response.

Stated Advantages

Cell and animal studies report inhibition of TLR7- and TLR9-dependent cytokine responses, including IFN-α and IL-6.

The reported influenza model shows reduced influenza-associated IFN-α production.

The reported acetaminophen model shows improved survival with the polynucleotide.

Reported results include suppression of CpG-associated NF-κB transcriptional activity and altered immune-cell counts and responses.

An immunoregulatory sequence increases plasmacytoid dendritic cell sensitivity to glucocorticoid-induced death and restores glucocorticoid responsiveness in lupus-prone mice.

The examples report reduced inflammatory gene expression in a mouse skin-inflammation model.

Documented Applications

Inhibiting an immune response by administering the claimed polynucleotide.

Treating or preventing autoimmune and chronic inflammatory disorders, including evaluation in a mouse skin-inflammation model.

Suppressing immune responses to microbial nucleic acids or gene-therapy vectors.

Evaluation of TLR7- and TLR9-associated responses in human plasmacytoid dendritic cells, B cells, and mice.

Evaluation of corticosteroid-related responses, including glucocorticoid responsiveness in lupus-prone mice and models involving hydroxycortisone and dexamethasone.

Evaluation of viral-induced responses, including influenza- and HSV-induced IFN-α outcomes, and disease models involving acetaminophen.

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.